COMMUNIQUÉS West-GlobeNewswire

Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024

06/05/2024 - 22:30

SAN DIEGO and TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat [...]

Day One Reports First Quarter 2024 Financial Results and Corporate Progress

06/05/2024 - 22:30

OJEMDA™ (tovorafenib) launch underway following U.S. FDA accelerated approval for relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) First prescriptions received in the U.S. BRISBANE, Calif., May 06, [...]

Immuneering Recognizes Melanoma Awareness Month

06/05/2024 - 22:30

- Two clinical stage product candidates in development for the treatment of melanoma - - RAS mutant melanoma represents one of five arms in the company’s ongoing Phase 2a clinical study of IMM-1-104 - - Melanoma also [...]

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

06/05/2024 - 22:30

(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 06 mai 2024 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]

Monthly information on share capital and company voting rights

06/05/2024 - 22:30

(Article 223-16 of General Regulation of the French financial markets authority) PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the capital [...]

T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into Equity

06/05/2024 - 22:29

Strengthens balance sheet by reducing total debt by approximately 80% over the past year Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated May 6, 2024 Relating to Preliminary Prospectus dated May 6, 2024 [...]

Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum

06/05/2024 - 22:15

— So far this year alone, 25 TULSA-related scientific research presentations have been delivered at major medical meetings around the world — — Of those, eight (8) presentations were from leading urologists at AUA 2024 [...]

SI-BONE, Inc. Reports Financial Results for the First Quarter 2024

06/05/2024 - 22:09

Annual guidance increased to $164 million - $166 million, implying annual growth of ~18% - 20% SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to [...]

Helio Genomics to Showcase Results from CLiMB Pivotal Trial in an Oral Presentation at the EASL Congress 2024

06/05/2024 - 22:05

IRVINE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Helio Genomics (“Helio” or “the Company”), an AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection, today [...]

Aileron Therapeutics to Present at Two Upcoming Investor Conferences

06/05/2024 - 22:05

AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet [...]

Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC

06/05/2024 - 22:05

If approved, Zeno will be the first targeted therapy for NRG1+ cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a [...]

Pennant Reports First Quarter 2024 Results

06/05/2024 - 22:05

Conference Call and Webcast scheduled for tomorrow, May 7, 2024 at 10:00 am MT EAGLE, Idaho, May 06, 2024 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated [...]

ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates

06/05/2024 - 22:05

Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC patients with EGFR exon 20 insertion, HER2 exon 20 insertion, or EGFR atypical mutations; updated Phase 1b data expected in the first half of 2025 Presented [...]

Sana Biotechnology to Present at May and June 2024 Investor Conferences

06/05/2024 - 22:05

SEATTLE, May 06, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations [...]

Telesis Bio Announces Reverse Stock Split

06/05/2024 - 22:05

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (the Company) (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible [...]

Regeneron Announces Investor Conference Presentations

06/05/2024 - 22:05

TARRYTOWN, N.Y., May 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast management participation as follows: RBC Capital Markets Global Healthcare Conference at 9:00 a.m. ET on [...]

Shockwave Medical Reports First Quarter 2024 Financial Results

06/05/2024 - 22:05

SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular [...]

NEXGEL to Present at the Aegis Capital Virtual Conference on May 9, 2024

06/05/2024 - 22:05

LANGHORNE, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content [...]

Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update

06/05/2024 - 22:05

- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Initiation of Phase 2 clinical trial for RT-102 for the treatment of osteoporosis expected in 2024 - - [...]